Key result
Childhood acute lymphoblastic leukemia survivors experience medical late effects from treatments like anthracyclines that increase their risk of premature death due to heart and vascular disease.
Population
Childhood acute lymphoblastic leukemia (ALL) survivors
Design
Review
Authors
Loading...
Supports cardiac surveillance in ALL survivors; leaves open optimal prevention trials for premature vascular mortality.
Childhood ALL survivors are at increased risk for long-term cardiac and vascular disease, necessitating interventions to improve long-term outcomes.
Ness et al. (2011) conducted a review in Childhood acute lymphoblastic leukemia (ALL). Childhood ALL treatment (particularly anthracyclines) was evaluated. Childhood acute lymphoblastic leukemia survivors experience medical late effects from treatments like anthracyclines that increase their risk of premature death due to heart and vascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: